Research programme: autoimmune disorders therapeutics - Mount Tam Biotechnologies

Drug Profile

Research programme: autoimmune disorders therapeutics - Mount Tam Biotechnologies

Alternative Names: TAM-01; TAM-02; TAM-03

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Biotica Technology; University of Cambridge
  • Developer Mount Tam Biotechnologies
  • Class Macrolides; Polyketides
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Systemic lupus erythematosus
  • Research Cancer; Multiple sclerosis

Most Recent Events

  • 13 Feb 2017 Early research in Cancer in USA
  • 07 Jul 2016 Mount Tam Biotechnologies/The Buck Institute for Research on Aging has patent protection for TAM 01 in USA
  • 03 Jun 2016 Mount Tam Biotechnologies intends to file an IND application with the US FDA for Systemic lupus erythematosus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top